Evidence map›Paper›PMID 34232486›Full record

ArticleInternal and emergency medicine2021

Does CHA2DS2-VASc score predict mortality in chronic kidney disease?

Christos Goudis, Stylianos Daios, Panagiotis Korantzopoulos, Tong Liu

Abstract read
In one paragraph

Article in Internal and emergency medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. CHAFrontiers in cardiovascular medicine · 2025
    Article
  6. Efficacy of CHAHeliyon · 2024
    Article
  7. CHAJournal of nephrology · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Predictive value of CHAThe Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2023
    Article
  12. Article
  13. Predicting mortality in hospitalized COVID-19 patients.Internal and emergency medicine · 2022
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Christos GoudisDepartment of Cardiology, Serres General Hospital, 45110, Serres, Greece. cgoudis@hotmail.com.
Stylianos DaiosDepartment of Cardiology, Serres General Hospital, 45110, Serres, Greece.
Panagiotis KorantzopoulosFirst Department of Cardiology, University of Ioannina Medical School, Ioannina, Greece.
Tong LiuTianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, 300211, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) is a leading cause of morbidity and mortality worldwide. Assessment of cardiovascular (CV) and all-cause mortality in CKD patients is of particular importance. CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes, prior stroke, vascular disease, age 65-74 years, and sex) score was originally formulated to predict the annual thromboembolic risk in patients with nonvalvular atrial fibrillation (AF). The calculation of R2CHADS2 and R2CHA2DS2VASc scores awarded an additional 2 points for CrCl < 60 mL/min and GFR < 60 mL/min/1.73 m

Indexed as

Atrial FibrillationFemaleForecastingHeart FailureHumansHypertensionMaleRenal Insufficiency, ChronicRisk AssessmentSex FactorsStrokeCHA2DS2-VAScChronic kidney diseaseMortality

Identifiers

PMID34232486
PMCPMC8261034

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.